Use of IV Iron and Risk of Anaphylaxis: A Multinational Observational Post-Authorisation Safety Study in Europe

• Published in: Pharmacoepidemiology and drug safety
• Main Authors: Fortuny, Joan, von Gersdorff, Gero, Lassalle, Regis, Linder, Marie, Overbeek, Jetty, Reinold, Jonas, Toft, Gunnar, Timmer, Antje, Dress, Jochen, Blin, Patrick, Droz-Perroteau, Cecile, Ehrenstein, Vera, Franzoni, Carla, Herings, Ron, Kollhorst, Bianca, Moore, Nicholas, Odsbu, Ingvild, Perez-Gutthann, Susana, Schink, Tania, Rascher, Katherine, Rasouliyan, Lawrence, Rothman, Kenneth J., Saigi-Morgui, Nuria, Schaller, Mathias, Smits, Elisabeth, Forstner, Michael, Benichou, Jacques, Bircher, Andreas J., Garbe, Edeltraut, Rampton, David S., Gutierrez, Lia
• Format: Journal Article
• Language: English
• Published: Wiley 28.06.2021
• Subjects: Life Sciences; Santé publique et épidémiologie; Dextran; Multidatabase; Anaphylaxis; Cohort study; IV iron; Severe hypersensitivity reactions

PURPOSE: This post-authorisation safety study estimated the risk of anaphylaxis in patients receiving intravenous (IV) iron in Europe, with interest in iron dextran and iron non-dextrans. Studies conducted in the United States have reported risk of anaphylaxis to IV iron ranging from 2.0 to 6.8 per...